Chapter 718

A bright light flashed past, and Norton immediately returned to his kind appearance, with a smile on the corner of his mouth, looking cheerful.

Jiang Lingyun came back to his senses, and immediately said: "Mr. Norton, I will arrange someone to meet with that Fade Chen immediately."

After finishing speaking, he paused, and said: "It's just that we just had a conversation with Fade Chen. If we meet again, we may—"

Norton shook his head, interrupted Jiang Lingyun with a wave of his hand, and said, "Don't bother."

"Mr. Norton, you—" Jiang Lingyun was a little puzzled.

Norton smiled and said, "I'll visit Fade Chen myself."

"Visit in person!" Jiang Lingyun was taken aback, and said in surprise, "Mr. Norton, you—"

Norton stood up straight away and said, "Go call a car, we'll set off right away!"

………

Fade Chen, who came back after the meeting, bid farewell to Tao Ling and Elder Du. He had just returned to the office and sat down, when a message came from the secretary outside, "Mr. Chen, is there a guest who wants to see you outside?"

"Who?" Fade Chen asked.

The secretary said: "President Jiang Lingyun Jiang of Jianghuhai Pharmaceutical."

"Jiang Lingyun, why is he here?" Fade Chen frowned, puzzled.

After all, their meeting just ended not long ago.

At this time, the secretary added: "There is also a foreigner, said his name is Norton."

"Foreigner, Norton!" Fade Chen thought for a while, and found that he didn't know this foreigner named Norton. He couldn't help being curious, but he still waved his hand, "I don't want to see them, let them go."

The secretary takes your lead, then turns around and goes out to convey the news.

But before the secretary went out, he saw Jiang Lingyun and Norton walking towards him.

"Sir, you can't—" the secretary hastily tried to stop the two of them.

Jiang Lingyun shouted coldly: "I want to see you, Mr. Chen!" Then he reached out and pushed the secretary away.

When Fade Chen saw this, he couldn't help but sneered, and said, "Mr. Chen, this is not your Jianghuhai Pharmaceutical. Your behavior, you'd better restrain yourself."

While speaking, Fade Chen waved his arm directly, sending out an invisible energy, which directly pushed Jiang Lingyun back.

Jiang Lingyun staggered a few times and almost fell.

Suddenly, his face was gloomy, with anger on his face, and he glared fiercely at Fade Chen, "Fade Chen, you dare to do anything to me!"

Fade Chen said coldly: "This is my office. If you break in, this is already the lightest punishment. Otherwise, there will be more ruthless ones. Does Mr. Jiang want to try?"

"You—" Jiang Lingyun was furious and was about to explode.

But at this time, Norton stood up with a smile, and directly said to Fade Chen in Chinese: "Mr. Chen, I'm sorry, we are reckless."

"Now, I'm paying an official visit to you, Mr. Chen. Is it convenient for Mr. Chen to meet us?" While speaking, Norton handed a business card to the secretary.

The secretary brought the business card in front of Fade Chen, and Fade Chen glanced at the content on the business card.

When his eyes fell on the title of "General Manager of Bald Eagle Pharmaceutical Asia Region", his eyes couldn't help but move, and he looked at Norton.

Norton looked at Fade Chen with a smile, looking extremely confident.

Fade Chen was silent for a while, looked at Norton and said, "If you have anything to do, just say it."

Hearing this, Jiang Lingyun couldn't help being furious, and shouted at Fade Chen: "Fade Chen, what's your attitude?"

"Mr. Norton is the top executive of Bald Eagle Pharmaceuticals, you are so negligent—"

Fade Chen said coldly: "I don't care if he is a bald eagle or a black-headed eagle. This is my company. If you want to say something, say it. If you don't say it, get out."

"You—" Jiang Lingyun pointed at Fade Chen, furious.

On the other hand, Norton, still smiling, stopped Jiang Lingyun, then looked at Fade Chen, and said, "Since Mr. Chen said that, then I will say it directly."

"Our Bald Eagle Pharmaceutical wants to cooperate with Mr. Chen. The content of the cooperation is the ephedra oral liquid that Mr. Chen has just developed. We want to—"

Hearing this, Fade Chen frowned, interrupted Norton's words with a wave of his hand, and said, "If it's about acquiring the patent of ephedra oral liquid, then needless to say, I will not agree."

Norton said with a smile: "Mr. Chen, don't rush to refuse. Why don't you listen to our conditions?"

"No matter what the conditions are, I won't agree." Fade Chen waved his hand.

Seeing this, Jiang Lingyun said angrily: "Fade Chen, this is Mr. Norton, this is Bald Eagle Pharmaceuticals, this is your chance, you—"

Norton stopped Jiang Lingyun, and said to Chen Fei: "I know that Chen is always a smart person, and he definitely understands the potential of ephedra oral liquid. So, I won't talk about those nonsense. I'll just say it straight, we at Bald Eagle Pharmaceuticals want ephedra oral liquid Liquid's patent—”

"This is impossible—" Fade Chen waved his hand.

Before Fade Chen could finish speaking, Norton said: "We are not going to buy out the patent of Ephedra Oral Liquid, but to cooperate with you, Mr. Chen, through a sharing model."

"As long as you agree, Mr. Chen, Bald Eagle Pharmaceuticals will immediately pay Mr. Chen 100 million US dollars. Afterwards, Mr. Chen can also get 5% of the profit of the drug."

Hearing this condition, Jiang Lingyun was shocked before Fade Chen responded.

He is a person in the pharmaceutical industry, so he naturally knows the value of Norton's conditions.

You must know that in the pharmaceutical industry, many laboratories and scientists around the world develop a lot of patented drugs every year, but due to the lack of production conditions and promotion conditions. These scientists and laboratories often sell the patented results of their research to major pharmaceutical companies.

Among them, the way of selling is generally divided into two types.

One is a one-time buyout, which directly transfers the patent rights of the drug to the pharmaceutical company, and the pharmaceutical company pays off the bill in one lump sum. In the future, the patent right of the drug will completely belong to the pharmaceutical company, and has nothing to do with the developer.

The other is the sharing model. The pharmaceutical company first pays a part of the property to the developer, and the subsequent profit distribution is based on the profit of the drug according to a certain proportion. That is to say, the more medicines are sold, the more profits will be shared.

Compared with these two methods, there is no doubt that the second sharing model has more potential. After all, once the drug is sold well, the developer can get a certain amount of profit from the benefit of every copy sold. The ultimate benefit will be longer-term and more lucrative. Much better than a one-time buyout.

Therefore, as long as the developers who are a little confident in the prospects of their own drugs want to use the sharing model to sell patents and obtain more profits.

However, developers know this, and drug companies naturally know it too.

Therefore, for the vast majority of drug patents, almost all pharmaceutical companies adopt the first buyout method.

If the other party disagrees, they would rather not buy it, or invest their own human, material and financial resources to directly develop similar drugs.